Meythaler & Zambrano achieved a key judicial victory overturning an arbitrary drug price cap, reinforcing due process and transparency in pharmaceutical regulation.

We successfully preserved a high-value family estate through judicial recognition of a post-mortem de facto union, thereby establishing a precedent in the field of succession law.

We achieved a second favourable SENADI resolution that strengthens test data exclusivity in Ecuador’s pharmaceutical sector.

Ecuadorian suppliers are under investigation for alleged money laundering and the use of offshore companies to hold assets within U.S. territory.

Ecuador’s IP law analyzed by Meythaler & Zambrano in Legal 500’s 2025 guide on trademarks, patents, and enforcement.

Ecuador’s 2025 Manual sets new rules for planning and procuring medicines and medical devices in the public health system.

Recognized in Chambers Latin America 2026 for Tax, Dispute Resolution, and Intellectual Property in Ecuador.

Meythaler & Zambrano secured the first SENADI ruling in Ecuador. This precedent strengthens IP rights in regulated industries such as pharma, agrochemicals, and biotech.

The Ecuador chapter, authored by Meythaler & Zambrano, offers practical guidance for pharmaceutical companies, insurers, and healthcare providers on regulation, pricing, public procurement, and digital health.

Prevent leaks and protect your confidential information. Legal strategies for trade secrets in Ecuador. Fast and effective advice.

Join the seminar to analyze new U.S. tariff policies and their impact on Ecuador’s business and investment environment. June 25 at AMCHAM Quito.

Discover how we updates regulations, protects innovation, and strengthens investment in pharmaceutical research in Ecuador.